Replies to post #799627 on NorthWest Biotherapeutics Inc (NWBO)

[learningcurve2020]

A hoax? Well, then shame on JAMA if that number of conflicts would normally prohibit them from publishing? I have not researched that aspect of it but do you know? I was under the assumption that they couldn’t be bought but who really knows in this strange new publication environment?

[SkyLimit2022]

seekazy,

“JAMA was a hoax” ?? 😶



I don’t think that you’re a credible source over independently peer-reviewed medical journals…

Are Nature Comms & JNS hoaxes too?

You better tell the 🇺🇲 U.S. NIH & the 🇺🇲 U.S. Department of War that they invested in a “hoax” because they awarded independently peer-reviewed grants to develop the DC platforms at UCLA & Roswell that are currently licensed to NWBO.



You also might want to advise Dr. Liau who is a member of the SAB at NWBO, and Dr. Kalinski & Dr. Ashkan who are consultants for NWBO…

In fact, there’s a long list of individuals & institutions whom you might want to advise about this “hoax.” 🙄

I think you will see a “hoax” if you look here:

Fact ✅️ Regarding the P3: Enrollment completed years before 2020, but patients continued to be treated & followed under the trial protocol as trial participants after enrollment closed. The P3 trial concluded in 2020, & data lock happened in Q4 of 2020…

Fact ✅️ Regarding Peer Review:
Independently peer-reviewed validation continues to expand! The U.S. NIH 🇺🇸 & U.S. DoD (DoW) have awarded & renewed rigorously peer-reviewed grants to support DC technology…

Additionally, there was another peer-reviewed publication presented recently at the SITC Conference!

Regulatory agencies may choose to consider independently peer-reviewed publications as part of their overall analysis. The MAA review is just one of several regulatory reviews to come as NWBO is developing several technologies/products. The examples below are relatively recent publications & Dr. Kalinski is currently working on another paper.



Nature Comms



JNS



JAMA Oncology

Fact ✅ Regarding MHRA:
The MHRA has already awarded several approvals, including their approval of the MIA (a prerequisite of the MAA) & their ongoing support of the DCVax-L Specials Program.

Mar 2023, NWBO & Advent MIA Approval


Aug 2022, NWBO PIP Approval


Dec 2021, NWBO & Advent GMP License Approval



COMBOS with checkpoint inhibitors & other agents are much more recent & have reached P2 for both DCVax-L & the Roswell DC technology platform.

⭐️Combo is King!⭐️




⭐️ Lifetime Achievement Award in Medicine, Dr. Liau

⭐️ AACR Advances in Ovarian Cancer Research

⭐️ NWBO to Acquire Advent BioServices

⭐️ Recent Conference

⭐️ DCVax-L Combo PII UCLA

⭐️ DC Combo PII Roswell Park

⭐️ 10-Q Quarterly Report

⭐️ 10-K Annual Report

⭐️ NICE UK 🇬🇧 DCVax-L

⭐️ ASM June 29, 2024

⭐️ Manufacturing Technology

⭐️ NWBO Acquires Flaskworks

⭐️ Roswell Park IP Portfolio

⭐️ TLR3 agonist Ampligen (rintatolimod)

⭐️ Next Generation Dendritic Cell Treatments




The Combo Era Begins

Fud Flood 🌊